Iroko secures $75m in debt for Zorvolex launch
This article was originally published in Scrip
Executive Summary
Iroko Pharmaceuticals pursued an initial public offering earlier this year, but later decided to rely on private investors – including a new debt provider – ahead of US FDA approval for the first few nonsteroidal anti-inflammatory drugs (NSAIDs) in the company's pipeline.